Affordable Access

deepdyve-link
Publisher Website

Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT.

Authors
  • Zong, Taili
  • Mei, Ling
  • Gao, Huile
  • Shi, Kairong
  • Chen, Jiantao
  • Wang, Yang
  • Zhang, Qianyu
  • Yang, Yuting
  • He, Qin
Type
Published Article
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier
Publication Date
Dec 01, 2014
Volume
103
Issue
12
Pages
3891–3901
Identifiers
DOI: 10.1002/jps.24186
PMID: 25339554
Source
Medline
Keywords
License
Unknown

Abstract

The development of a drug delivery strategy that can not only cross the blood-brain barrier (BBB) rapidly, but also target the glioma and reach the core of glioma is essential and important for glioma treatment. To achieve this goal, we established a dual-targeting liposomal system modified with TAT (AYGRKKRRQRRR) and T7 (HAIYPRH), in which the specific ligand T7 could target BBB and brain glioma tumor and the nonspecific ligand TAT could enhance the effect of passing through BBB, and elevate the penetration into the tumor. The dual-targeting effects were evaluated by both in vitro and in vivo experiments. To identify the targeting effect, in vitro cellular uptake and BBB model were performed. Tumor spheroid penetration was performed to evaluate the penetration characteristics of the dual-targeting liposomes. In vivo pharmacokinetic studies were utilized to evaluate the influence of T7 and TAT peptides on the behavior of nanoparticle drug delivery system, and tissue distribution was further utilized to evaluate the glioma-targeting efficiency of the dual-targeting liposomes.

Report this publication

Statistics

Seen <100 times